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Unresolved Tax Issues
in Viatical and Life Settlements
Bruce Evans, Tim Fontenot,
Barbara Scofield, Bill Shoemaker, and Robert Walsh
Viatical and life1
settlements refer to the
ownership transfer of a life
insurance contract for
valuable consideration.
These settlements provide
seller liquidity and investor
return that has little corre-
lation with other asset
classes and investment
markets. The pricing of life
settlements, and thus the
funding to individual policy-
holder sellers, are directly
affected by the tax
consequences of the proceeds
subsequently paid to
investors. This article
explores the current tax
environment for life settle-
ments and explores possible
tax contexts that would affect
the sharing of the insurance
proceeds among the insured
seller, the investor, a life
settlement company, and the
various tax authorities.
Alternative interpretations of
the life settlement transaction
are provided so policymakers
can make informed choices
with respect to tax, as well as
social, policy involving the
terminally-ill. 
The longstanding choices
of the insured and their heirs,
receiving the cash surrender
value of a life insurance policy
or waiting for the proceeds at
death, are contrasted with life
settlement options that offer
returns to investors in the
form of ordinary income,
capital gains, or tax-free
subrogation or assignment.
Obviously, the option that
provides the greatest current
funding to the insured and
the greatest return to the
investor is the tax-free life
settlement subrogation or
assignment, which preserves
the original tax-free character
of life insurance transactions.
Overview
The first section of this
article describes the life
settlement market, its
stakeholders, and individual
investor perspectives. It
then provides a general
example of the life settle-
ment contract and its
functions. Next, the general
tax treatment of life settle-
ments for investors in these
policies is investigated.
Subsequently, the
alternative tax treatment 
are considered. Finally, the
comparative implications of
the tax treatment are
demonstrated.
The Life Settlement
Market
The life settlement
market began as the sale of
life insurance policies by the
terminally-ill to another
party for less than the death
benefit of the policy. The
new policyholder is respon-
sible for any premiums after
the transfer and, upon
death, receives the death
benefit from the policy.
Since transferees pay less
than the face amount of the
policy, they receive some
return on this investment,
depending on how much
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longer the transferor lives
after the transfer. 
As these life settlements
have grown over the past
dozen years, the market has
shifted from institutional
investors to include
individual investors as well.
This form of secondary
market for life insurance
policies has risen from $13
billion in face amount of
policies transferred in 1995
to $160 billion in 2004
(Simon and Schmitt 2006). 
The current life
settlement market is divided
into the segment for the
terminally-ill insured/
policyholder and the
segment for any life
insurance policy sale by
someone else. While
institutions can participate
directly with an insured,
individual investors typically
use an intermediary to
match potential sellers and
potential investors. The Life
Settlement Association
(2007), a trade association
for companies involved in
viatical and life settlements,
has members from 58
brokers who negotiate sales
on behalf of sellers spread
across 48 states plus the
District of Columbia. On
average there are 11
licensed brokers who are
members of the Life
Settlement Association in
each state.
Life settlement
companies provide the
services that coordinate the
sale and investment. The
due diligence and the
paperwork in the public
offering of life settlements
are substantial. The life
settlement company verifies
information about life
expectancy of the insured
and obtains authorization
from beneficiaries. Several
individual investors may
participate in ownership of a
single life insurance policy,
and each individual investor
may purchase an interest in
several life insurance
policies. The life settlement
company manages the
payment of subsequent
premiums through an
escrow account, tracks
notification of deaths, and
receives and distributes the
life insurance proceeds.
They have a dual marketing
role in both establishing
contacts with those
interested in receiving
accelerated death benefits
and identifying appropriate
investors. The closing costs,
including the due diligence,
prepayment of premiums for
a projected period and
commissions to brokers,
usually amount to ten to
fifteen percent of the
investment/purchase price
of the insurance policy.
These closing costs are
typically paid by the insured
from his or her proceeds
and do not affect the return
to investors.2
All parties to the sale are
considered to benefit.3 The
original policyholder is able
to sell his policy for an
amount substantially
greater than the cash
surrender value typically
found in whole life policies,
and the investor is able to
achieve a corresponding
return on this life settlement
contract while avoiding most
of the risks associated with
the equity markets and far
exceeding the current
market rate of a low risk
bond. The investor retains
the uncertainties of when
the policy will mature since
it depends on when the
insured dies, and the
possible payment of
additional premiums if the
insured lives beyond the
projected period. Within
these investment para-
meters, the risks for the
investor are generally
diversified by the investor
purchasing an ownership
interest in several policies of
various insured persons.
Prior to the emergence of
the life settlement industry,
taxation of life insurance
proceeds was well defined.
When an individual dies,
Section 101 of the Internal
Revenue Code classifies the
life insurance proceeds as
generally free of federal
income taxation to the
beneficiary.4 Terminally-ill
individuals frequently sold
their policies in the 1980's
and 1990's, precipitated
principally by a rise in
terminally-ill AIDS patients.
Section 101(g)(1)(A) and
7702B of the Internal
Revenue Code were added
by the Health Insurance
Portability and Account-
ability Act of 1996 and
clarified that proceeds from
the sale of a life insurance
policy to a life settlement
company are a tax-free
death benefit to the
terminally-ill patient (Raby
and Raby 2000). 5 
The taxation of the
eventual proceeds of life
policies to investors has not
been directly addressed in
the tax code. The current
tax treatment is based upon
precedent from court cases
for ordinary income tax
treatment of the life
settlement proceeds to the
investor. The following
example assumes the tax-
free treatment of proceeds to
the insured seller and
ordinary income tax
treatment for the proceeds
to the investor.
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60's that would
absorb a lot of water.
Until we converted it
into a Pampers
disposable baby
diaper, it was just a
new kind of material.
We created this
entirely new product
category, and that
created an industry
(Crockett, 2009:
p.44).
A number of manage-
ment approaches can be
used to derive and preserve
the value potential. Internal
strategies may find it
beneficial to develop an
innovation at a lower level of
funding, allowing progress
and evolution while
preserving resources.
External strategies may
realize value from external
partnerships or licensing
revenues. Many times
significant innovations that
are not related to current
operational or strategic
plans can find a home in a
spin-off organization or joint
venture. Whether within the
current organizational
structure or outside of it, at
the current point in time or
sometime in the future,
innovation provide real
value that should not be
abandoned. 
Conclusion
The establishment of the
value of innovation to a firm
is difficult to quantify. As
our understanding of the
full impacts of innovation on
the firm evolves, the
methods that we use to
capture this value changes.
There are three significant
implications to management
practice from these results.
1. The measurement tools
that we utilize determine
the innovations that we
select and implement,
not visa versa. When the
only tool that you have
is a hammer, everything
looks like a nail. When
the only innovation
metrics that we use
focus on cost reduction
exclusively, the only
innovations you will
identify are those
incremental and process
innovations that reduce
cost. Care should be
given to the evaluative
techniques implemented
because they will, in
large part, determine the
character of the results.
2. Innovation valuation
metrics must be selected
that take into account
the secondary impacts of
an innovative idea. The
implications of not
pursuing an idea or of
the longer-term value of
an idea must be
measured. These
impacts on value to the
firm may be much
greater in scale than a
static evaluation.
3. Innovation ideas that
the organization decides
not to pursue, for
whatever reason, should
not be abandoned.
Additions to the firm’s
knowledge base may
lead to other synergistic
developments. As
circumstances, markets
and strategies change
over time, the value of
an innovation to a firm
may change drama-
tically. For this reason,
the knowledge base of
unimplemented innova-
tions should be
periodically and syste-
matically revisited.
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Basic Example of a
Viatical/life Settlement
Transaction
An elderly, terminally-ill
life insurance policyholder
seeks to sell her $1,000,000
face value death benefit
policy as soon as possible
for as much money as
possible as outlined in
Figure 1. She desires to
obtain cash now while she is
living rather than later for
her estate or heirs upon her
death, and she qualifies for
tax-free treatment of her
proceeds. The insured has
paid total premiums of
$175,000 over the life of the
policy so far, and the cash
surrender value is
$200,000. The policyholder
has a life expectancy of
three years, but some
potential for survival to five
years. The investor
conservatively bases his
offer on the outside time of
five years. 
In this case, the investor
offers $500,000 to the
policyholder in order to
become the new owner of
the policy and name himself
the new beneficiary. Closing
costs of $75,000 cover the
commission for the
insurance broker, due
diligence of the life
settlement company, five
years of future premiums,
and overhead and profit of
the life settlement company.
Assuming the policy is paid
upon death at the end of five
years, the investment will
provide $425,000 to the
insured immediately as
reflected in Panel A and
yield 14.87 percent
compounded annual return
to the investor (for more
information as to how this
compounded annual return
varies by survival period
and tax treatment, see
Figure 3, page 17, which
reflects declining returns for
longer survival periods).
Panel B provides a
comparison of the
distribution of the proceeds
of the life settlement when
the insured/policyholder
does not qualify as
terminally-ill/chronically-ill
and must pay taxes at
receipt of the life settlement
proceeds. Note that current
tax policy offers a $42,000
benefit to the terminally- or
chronically-ill insured seller
over the average senior
citizen insured seller.6 
The alternatives reflected
in Panels A and B provide
current liquidity that is
absent if the policy pays the 
estate, or heirs, at death.
The alternatives are larger
than the equally liquid cash
surrender value shown in
Panel C. Note that the taxes
at the time of the life
settlement transaction are
solely those paid by the
broker on his fee income
and by the life settlement
income on its earnings.
Figure 1
An Example of Distribution of Life Settlement Investment
Assumptions:
Face Amount of Policy $1,000,000
Premiums Paid $175,000
Cash Surrender Value $200,000
“Maximum” Life Expectancy 5 years
Price Paid in Life Settlement $500,000
Closing Costs $75,000
Annual Premium on Life Insurance $7,000
Broker Commission as % of non-premium closing costs 50%
Life Settlement Company Return on Closing Costs 10%
Ordinary Income Tax Rate to Life Settlement Company 35%
Ordinary Income Tax Rate to Broker 25%
Ordinary Income Tax Rate to Insured/Policyholder 33%
Capital Gains Tax Rate to Insured/Policyholder 15%
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Broker/Life 
Settlemen t 
Com pany, $34 ,300, 
7%
Escrow,  $35,000,  
7%
Taxes, $ 5,700, 1 %
Insured / 
Polic yholder, 
$425, 000, 85%
Taxes, $47,700, 
10%
Escrow, $35,000, 
7%
Broker/Life 
Settlement 
Company, $34,300, 
7%
Insured /  
Policyholder, 
$383,000, 76%
Panel A
Terminally- or Chronically-Ill Insured Policy Seller Distribution of Investor’s $500,000 Payoff
Note: Tax is the sum of (a) tax paid by the broker on fee income [($75,000-$35,000)*.50*.25] and (b) tax
paid by the life settlement company on its profits [($75,000-$35,000)*.50*.10*.35]. The assumed tax
rate is the maximum marginal tax rate by tax entity, consistent with other studies and shown to be
reasonable by Jensen, Kaplan and Stiglin, 1989.
Panel B
Senior Citizen Insured Policy Seller Distribution of Investor’s $500,000 Payoff
Note: Tax is the sum of (a) tax paid by the broker on fee income [($75,000-$35,000)*.50*.25], (b) tax paid
by the life settlement company on its profits [($75,000-$35,000)*.50*.10*.35], (c) tax paid by the
insured on the proceeds over the cash surrender value at the capital gains rate [$425,000-
$200,000)*.15] and (d) tax paid by the insured on the difference between the premiums paid and the
cash surrender value at the ordinary income rate [($200,000-$175,000)*.33].
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product, process or service.
These may be impacts on
value derived from changes
to the organization, its
structure, culture, markets,
other innovations, and
client or supplier
relationships.
Risk becomes an
important consideration in
the innovation evaluation
process. As the element of
risk becomes a more
significant factor in the
valuation of an innovation,
the precision and likelihood
of an accurate evaluation of
the idea’s benefit to the
organization becomes
smaller. The concept that
increasing uncertainty for
estimates of cost reductions
or profit potential leading to
a lowered expected value
and reduced valuation of the
idea is straightforward.
However, when we turn to
measuring other value
returns on an innovation,
such as the secondary
effects, uncertainty plays a
greater role. An example of a
significant secondary effect
is the value to a firm of
introducing a new product
that gives it “first mover”
status in the marketplace.
While we may accurately
estimate our product sales
in a new market, rarely is
the more significant factor of
the value to the firm of
being able to shape the
market with it innovation
quantified. Indeed, a firm’s
ability to define the
taxonomy and salient
factors of a new market will
generate value to the firm
long after the value of the
specific product being
introduced has passed.
Think of the value generated
for an IBM or Microsoft
through defining a market
that continued long after
their initial product
introductions had faded
from the marketplace. In
hindsight this value is clear,
yet a priori, it is rarely
included in the valuation of
an innovation. When we are
unable to quantify the
impact due to uncertainty,
we tend to negate it and
ignore it completely.
Unfortunately, ignoring
what we cannot quantify
leads to the same set of
assumptions as if it had no
value.
Whenever a value
assessment is made outside
of the current context, risk
plays a part in that process.
However, this does not
mean that we discard all
concepts of value that
contain a level of
uncertainty. Risk is
quantified and incorporated
into the value assessment.
These risk quantification
techniques provide a
window into methods that
may be able to more
completely capture the full
value impacts of innovation.
An additional secondary
effect is the chaining effect
that innovation takes. One
idea leading to another. In
and of itself, an innovation
may not prove valuable
enough to pursue. Yet it
may lead to a stream of one
or more related ideas and
innovations, which may
prove valuable. The
potential for this chain of
events may or may not be
apparent at the time an
innovation is evaluated.
Anecdotal evidence of these
events is prevalent, however,
unfortunately only apparent
in retrospect. Such
examples are strong enough
to inform our actions to not
preclude their possibility.
Preserving the Value
of Innovations Not
Pursued
The body of literature on
innovation measurement
metrics that discusses the
need to align the
measurement and valuation
process with the
organization’s strategy is
extensive (Vossen, 1999;
Neely et al., 2000). While
this approach has value in
the static and immediate
timeframe, it misses a much
more important aspect of
valuation of an innovation
over time. Following this
strategy we can conceive of
innovations being
abandoned for a variety of
reasons bound to the
immediacy of the criteria
that are used to evaluate
them. Innumerable
examples from almost any
firm engaging in R&D in
which important innova-
tions were abandoned
because of a lack of
immediate resource
availability to develop them
exist. This is under-
standable from an
operational standpoint, but
should this necessarily lead
to an abandonment of the
innovation and the forfeiture
of all the value that it can
produce? In a recent
interview A.G. Lafley, the
CEO of Procter & Gamble
discussed an innovation
that manifested value at a
later point in time and in an
unexpected way;
We invented a
material back in the
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YRC Worldwide not punish
failures, but celebrates
them. Zollars elaborates on
an occasion when it was
clear that an innovation
implementation was failing;
…but we did it
anyway, even though
I knew it was going
to be a mess,
because it was more
important for us to
say, ‘Look we’re
trying stuff even
though we’re not
sure its going to be
successful,” than it
was to say, “No,
that’s a stupid idea,
we’re not going to do
it,” (DOC, 2008: 11-
12).
Creating a failure-
tolerant environment for
innovation hypothesis
testing and experimentation
does not do as much to
guide the behavior of an
employee with an insight as
it does to remind us that all
ideas have value. This
approach informs us on how
processes that capture value
should be structured. When
we create an internal
climate that encourages
individual creativity and
openness, whom are we
really talking to? The
greatest affect of such an
organizational change may
not be our employees, but
the organization’s culture
and value system. McAdam
and Keogh (2004) find
additional empirical support
for the modification of the
systems of innovation
measurement into more
fault tolerant processes. One
of the benefits they find is in
overcoming past
disillusionment from
rejected ideas. When such
approaches are successful is
it because more innovative
ideas are developed and
presented by employees, or
is it because we are
sensitizing ourselves toward
hearing the stream of ideas
already flowing there?
Increases in the innovation
output may be caused more
by changes to the
organizational receiver
rather than the sender. 
Failure of the processes
and techniques used within
an organization to resolve
problems may serve as a
significant source of
innovation. Thomas Kuhn
(1962) describes that the
pressure for change in the
prevailing assumptions and
conceptual framework in a
discipline comes from an
increasing accumulation of
anomalies that are
inconsistent with them over
time. Many times the
pressure for change that
generates or brings
innovations to the surface
are generated from a
Kuhnian disfunctionality in
how the current technology
and processes meet the
needs of the specific
circumstances in the
organization. The
organization finds that the
attempt to solve problems
with existing processes and
approaches is less and less
functional. The developing
realization that the current
systems are increasingly
dysfunctional, opens the
organization up to the
possibility of alternative
solutions. It is the energy
behind this increasing level
of discomfort that motivates
the search for new and
innovative solutions. This
pressure also focuses the
attention of value measure-
ment upon the “goodness of
fit” criteria as a solution to a
specific set of problems.
The results found in the
academic literature of the
1980's and 1990's with
organizational prescriptions
for generating innovation
through the construction of
nurturing and participative
environments to elicit and
develop ideas has been
tepid, at best. On the other
hand, the somewhat
disturbing data from
organizational creativity
studies has found that
many times innovations
from the shop floor find
their birth in anger,
frustration and desperation.
Canner & Mass’ (2005)
contend that innovation is
motivated by desperate acts
needed to keep operations
running rather than by a
creative environment. In this
case, desperation reduces
the risk of having an idea be
perceived negatively. This
motivates the innovator and
makes them more willing to
share their insights. More
significantly, desperation
may change the perspective
of managers making them
more receptive and attentive
to innovative solutions being
presented to them.
Evaluating the
Secondary Effects of
Innovation
The secondary effects of
innovations upon an
organization may be greater
and more profound that
those related to their
immediate application. By
secondary effects, we mean
those impacts that
innovation has upon the
firm that are not directly
related to the immediate
reflection of value in a
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Taxes, $8, 250,  2%
Opport unity Cost, 
$300,000, 60%
Insured / 
Policyholder, 
$191,750, 38%
Panel C
Cash Surrender Value Only Distribution Based upon Investor’s $500,000 Payoff Equivalent
Note: Tax is ordinary income tax on the difference between the premiums paid and the cash surrender
value [($200,000-$175,000)*.33]
The taxability of the
$500,000 gain realized by
the investor when he
collects the $1,000,000 face
value upon the death of the
insured is the subject of the
subsequent analyses. To
focus on the primary issue
of this article, the
alternatives all assume that
the transaction would be
tax-free to the insured if she
participates in a life
settlement and to the heirs
if they receive the face value
at the insured’s death.
Federal Tax Ramifications
of a Viatical/life
Settlement Payment
The tax ramifications of
the sale of a life insurance
policy to a life settlement
company and subsequent
sale by the company to an
investor, in most cases, are
more clearly defined,
specifically the tax
treatment for the terminally-
ill seller. However, current
ordinary income tax
treatment for the investor is
predicated upon legal
precedent in which a capital
gain argument has
substantial support. 
Continuing the previous
example, the return to the
insured seller and her heirs
from the life settlement
represents an immediate
tax-free 6.29 percent
compounded annual return
on premiums paid reflected
in Figure 2. Should the
insured continue the policy
until her death, the return
to her estate, or heirs, is a
function of her survival and
declines from 11.03 percent
with a single year of survival
to 7.93 percent with seven
years of survival. Thus, the
insured has the classic
investment decision of
immediate certain proceeds
versus a variable future
return. In the absence of life
settlements, the only
alternative that also
provides immediate liquidity
is ending the policy and
receiving the cash surrender
value, as reflected in Panel
C. In this example, life
settlements provide 128
percent more cash
($425,000 versus $191,750)
than the cash surrender
value alternative.
On the other hand,
suppose the woman sells
the $1,000,000 policy to a
life settlement company for
$425,000 net cash, which is
tax-free to her. The life
settlement company then
sells it to an investor(s) for
$500,000, and the investor
can expect to receive
proceeds of $1,000,000 at
the policyholder’s death.
The difference between the
investor’s payment and the
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6.2 9%
11.03%
10 .40% 9.82%
9.29%
8.80% 8.35% 7.93%
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
1 2 3 4 5 6 7
Return from Life Settlement Return from Life Insurance
Figure 2
Comparison of Return to Insured/Heirs from Life Insurance vs. Life Settlement for
Survival Periods of One to Seven Years
Assumptions:
Face Amount of Policy $1,000,000
Price Paid in Life Settlement $500,000
Closing Costs $75,000
Annual Premium on Life Insurance $7,000
Total Premiums Previously Paid at Time 0 $175,000
Years of Premiums Previously Paid at Time 0 25 years
insured’s receipts include
escrow for future premiums,
compensation to the broker,
and payment for closing
costs and profit of the life
settlement company. When
the elderly woman then
dies, the investor receives
$1,000,000 in cash. The
difference between the
investor’s proceeds of
$1,000,000 and his basis or
cost in the asset of
$500,000 is realized gain of
$500,000.7
How Should this Realized
Gain Be Taxed? 
The Research Institute
of America’s Federal Tax
Coordinator states, “Any
taxable gain on the sale or
surrender of a life insurance
contract is treated as
ordinary income…”
(Research Institute of
America 2006 Para J-5307).
The basis of this statement
is the interpretation of a
number of cases, including
Estate of Rath v. U.S. (1979)
and Gallun v. Commissioner
(1964). In Estate of Rath v.
U.S. (1979), Rath’s wife
purchased for around
$11,000 the life insurance
policy from her husband’s
corporation on her
husband’s life. A few years
later, her husband died. The
IRS assessed a tax on the
difference between the life
insurance proceeds of about
$100,000 and the basis of
$11,000 that Mrs. Rath had
paid for the policy. The
Sixth Circuit Court upheld
the treatment of ordinary
income to Mrs. Rath of
about $89,000, saying such
treatment was consistent
with Section 101 (a) (2) of
the Internal Revenue Code,
which covers transfer for
valuable consideration. One
issue is not that the Sixth
Circuit found the amount of
$89,000 to be taxable, but
that it was labeled as
ordinary income and not
capital gain.
In Gallun v. Commis-
sioner (1964), the taxpayer
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that an innovation’s value is
determined by a user group
who has a vision of what it
can do for them.
When we relate these
societal perspectives to an
organization, the contextual
nature of innovation’s utility
becomes clear. Those who
bring the innovation to the
specific organizational
context are primarily
responsible for determining
and advocating the value
metrics for its efficacy.
While the originating
organization may not find
value, the circumstances
existing in another
organization may find
immediate value. Inde-
pendent of its intended
application or original value
measurement, it is the
evaluative framework that a
champion or user group
applies to the idea from
within their own context
that proves determinant.
This not only confirms the
distinct nature of the
valuation configuration
between firms, but also that
the valuation configuration
within a firm may vary over
time, group dynamics and
other circumstances.
The bias toward
establishing innovation
valuation metrics that
directly relate to the current
product offering
configuration, markets and
processes leads to a skewed
view of the content that
passes through these filters.
Innovations that relate to
the current context find
higher valuation than those
that do not because of the
relevancy to the metrics.
This leads to adaptation of
incremental innovation
because they better relate to
our frame of reference, than
more disruptive innovation
that does not.
Unfortunately, this
comparison is usually
couched in the rubric of
“valuation” when there is
little actual value
comparison being made.
The true value of a
disruptive innovation that
does not fall within current
plans and strategies is
rarely assessed.
One of the examples
where metrics missed
important value has become
part of our popular culture.
In 1968, 3M researchers
developing adhesives
produced a substance that
due to its molecular
structure would cling to
objects but was too weak for
a permanent bond. Due to
its poor adhesive properties,
the innovation languished.
In the mid 1970s Arthur
Fry, another researcher at
3M, found that if the
adhesive was applied to
paper, it would allow him to
bookmark the pages of his
church hymnal without
staining the page. This new
use allowed for the
application of a different set
of valuation metrics.
Evaluated for its traditional
adhesive characteristics,
this substance would have
been abandoned. In 1980,
3M introduced the Post-It
Note and created a
completely new product
category (Wikipedia, 2009).
We are faced with the
conclusion that innovation
should not be discarded,
since it is inevitable that
they will find value in some
context. The issue for
managerial practitioners is
to find the correct context
through which to capitalize
on this value. 
Failure Has Value
There are a variety of
reasons why an innovative
idea never becomes realized
in the marketplace. There is
innovation that is missed
because an employee never
expresses the idea or shares
his insight. This may be
caused by perceived or
actual penalties associated
with a failure. There is some
evidence that anonymous
methods of contributing
ideas in an organization
may enhance participation
and contribution levels. By
reducing the perceived risk
to participants of offering
ideas that might be seen
negatively, anonymity
increases their willingness
to participate. Valacich et al.
(1994) found that
anonymous submission may
increase the willingness to
participate by reducing the
perceived risk of offering
ideas that might be seen
negatively.
Anecdotal evidence
supports the impact of fault
tolerant environments on
the production of
innovation. In a Forum on
Innovation, conducted by
the U.S. Department of
Commerce (2006), William
Zollars the Chairman of YRC
Worldwide discussed his
firm’s innovation
management policy. YRC
Worldwide, formerly Yellow
Freight, combines a fault
tolerant environment with
strong decentralized
decision-making. This
provides for a more direct
hypothesis-testing context
at the point closest to where
the innovation is generated.
This leads to effective
exploration of the idea and
responsibility for its
evaluation. Not only does
24 Summer 2009 Southern Business Review
services sector firms with an
innovation in the past three
years, 16 percent created an
innovation new to the
market, while 77 percent
produced an innovation new
to the firm. (p.525)
Pavitt’s (1984) work
studying the sources of
2000 British technological
innovations during the time
period 1945-1980 revealed
that an organization’s
industrial sector was a
significant determinant in
the type of innovations that
a firm pursued. Firms in
industries that were
strongly customer-centric
realized more new product
or service based innovation,
while firms in more
production intensive sectors
increased cost cutting
process related techno-
logical innovation.
While this reinforces the
idea that there is no single
set of innovation measure-
ment metrics that can be
applied to all firms, it may
be related to an underlying
flaw in managing the
application of the metrics.
The sectoral variance in
capturing different classes
of innovation may be caused
by only applying those
metrics that have direct
relevance to a current
operational strategy.
The results developed by
Pavitt (1984) may be caused
by the decisions made on
which innovation
measurement metrics to
use, rather than the overall
potential value to the firm.
It’s like the joke about the
man looking for his lost
keys under a streetlight one
night. When a passerby
offers to help in his search,
he asks, “Where do you
think you dropped them?”
The man responds “About
100 meters down the
street.” “Then why are we
looking here?” the passerby
asks. The man responds,
“Because the light is better
here.” As managers, we seek
out innovation where the
light is better.
Innovation and the
Value of Failure
The concept of failure
has several connotations in
the context of innovation
value measurement.
Failures in adequately
capturing the value of the
innovation by due to
inadequate or incomplete
application of the valuation
metrics abound. Ches-
brough (2004) discussed the
need to measure and
manage “false negatives” in
the innovation process. He
discusses “false negatives”
as innovation efforts that
have been terminated or
abandoned by an
organization which later
show renewed value. The
termination may be because
the innovation relates to
markets outside of those
that the organization
currently pursues. It may be
because the innovation
relates to a market that is
currently undeveloped. In
both cases, the organization
finds renewed value in the
“false negative” at a later
point in time. Chesbrough
highlights the need to
regularly revisit the
knowledge base created by
terminated innovation to
reevaluate the internal and
external value of these ideas
and to develop strategies to
capitalize upon them.
Another implication to
innovation measurement
can be drawn from this
work. By discussing the
nature of error in valuation
metrics for innovation and
the need to revisit these
evaluations, Chesbrough
highlights the fact that
almost all valuation metrics
for innovation are static
measures. The value of an
innovation is made based
upon an assessment at a
specific point in time. This
point in time assumes that
an organization’s markets,
structure and strategies are
parametric. The possibility,
even probability that these
circumstances will change
over time is obvious.
Labeling an innovation as a
failure and discarding it
from our organizational
knowledge base precludes
any possibility of reaping
value from its application in
another day.
Another type of failure in
innovation valuation is the
failure to use appropriate
measures that capture all
aspects of value to the firm.
The literature on the social
shaping of technology
addresses technological
innovation from a
sociological standpoint as
being generated and shaped
by competing interest
groups. These interest
groups each have a vision of
the potential of a technology
and vie for the resources
and acknowledgment of
their point of view. Pinch &
Bijker (1984) or MacKenzie
& Wajcman (1999) are
examples of a literature that
accents these dynamics in
the selection and imple-
mentation of innovations.
The significance of this
theory is twofold. First, that
it identifies that users
appropriate technology and
use it in way unforeseen by
the inventor and second,
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transferred several policies
worth a total of $250,000 in
face amount with an
accumulated premium cost
of around $121,000 and a
cash surrender value of
$159,000 to the corporation
in which he was CEO. He
claimed a capital gain of
$38,000. Both the Tax
Court and the Appeals
Court ruled this $38,000
was ordinary income, since
it represented the
accumulated of deferred
interest income, the excess
of cash surrender value over
premium cost. To allow
capital gains treatment
would have been effectively
allowing conversion of
ordinary income into capital
gains.
On the basis of these
two legal cases, typical life
settlements, such as the
example, would have the
following tax result. The
$1,000,000 proceeds less
the basis, or cost, of the
policy of $500,000 is
ordinary income of
$500,000 to the investor
(see Figure 3). The $500,000
could represent interest
from the investment in the
policy; hence, there would
be ordinary income tax
treatment. 
Or Is It?
First, Section 101(a) (2)
defines the “transfer for
valuable consideration” as
merely giving rise to income,
not whether it is ordinary
income, capital gain, or non-
taxable income. In an article
by Magner and Leimberg
(2006), some life settlement
companies specifically
market their products with
the statement “…amounts
received in excess of cash
surrender value are
generally taxable as capital
gain…” along with the words
following that
Figure 3
Comparison of After-tax Returns to Life Settlement Investor 
For Survival Periods from One to Seven Years
Face Amount of Policy $1,000,000
Closing Costs $75,000
Price Paid in Life Settlement $500,000
Annual Premium $7,000
Life Expectancy (“Max") 5 years
Ordinary Tax Rate to Investor 33%
Capital Gains Tax Rate to Investor 15%
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statement of “please consult
your own tax and financial
advisors ….”
It is well established that
the gain on the surrender of
a life insurance policy is
ordinary income to the
insured (Section 72(e))
unless specifically to a life
settlement company or other
purchaser from a
terminally-ill person. This
tax treatment is consistent
with the position that the
ordinary income is created
from the excess of the cash
surrender value over
premiums paid. Yet, life
settlement companies have
argued that a life insurance
policy is a capital asset in
the hands of one of its
investors; therefore, any
proceeds over the basis or
cost of the policy should be
capital gains.
The capital asset
argument has merit on two
counts. First, the life
insurance policy itself is a
capital asset under Section
1221 of the Internal
Revenue Code. That section
defines everything which is
not a capital asset (stock in
trade, property held for sale
to customers, etc.). Since life
insurance policies are not
listed, they can be
considered capital assets.
Sales of capital assets
generate capital gains,
either short-term or long-
term, but capital gains
nonetheless.
The second case for
labeling the proceeds less
basis as a capital gain is
more complex but also
worth consideration.
Suppose in the above
example, before the elder
dies, the investor, who has a
basis already in the policy of
$500,000, finds someone
else who is willing to pay
$800,000 for the policy. The
sale is consummated, and
the original investor now
has taxable income of
$300,000 ($800,000 of
proceeds less $500,000 of
basis). This would appear to
be a capital gain, being a
return from the sale of an
investment. By parallel, the
same argument is made
that, upon death, the policy
ends with a “sale” of the
policy to the original
insurance company for
$1,000,000, hence a capital
gain of $500,000.
The capital gains
treatment of the insurance
proceeds that are more than
the investor’s basis
increases the return of the
investor, if this case is
treated statically. However,
changing the after tax
return to the investor would
allow other investors to
compete for the policy at a
lower cost. Thus if the
investor were originally
seeking an after tax 10.80
percent return, as in this
example, then the change in
tax treatment would enable
the investor to earn this
return with an increased
offer to the insured/
policyholder. Solving for the
investment that would
result in an after-tax rate of
return of 10.80 percent
given capital gains
treatment, the investor will
make an offer price of
$554,000, a 10.8 percent
increase, freeing funding
that previously paid for
taxes into direct funding to
the insured, who receives it
on a tax-free basis.8
Alternatively, capital
gains treatment may still be
available to some investors
in some circumstances even
if ordinary tax treatment
holds. An actual resale of a
life settlement by one
investor to another in a
tertiary market for already
vetted and packaged life
settlements would generate
capital gains to the original
investor.9 
The Case for
Alternative Tax
Approaches
Challenges are present
in the legal interpretation
concerning applicable
taxation of life settlement
investment gains. Taxing
the investor’s gain as
ordinary income or capital
gains, as previously
described, changes the tax
character of the original life
insurance transaction. The
twin challenges offered
advance alternative
positions that such gains
are not to be taxed at all,
being instead either a)
subrogation recoveries or b)
assignment proceeds.
Subrogation is defined
as follows: 
The substitution of
one person in place
of another with
reference to a lawful
claim… so that he
who is substituted
succeeds to the
rights of the other
(Black’s Law
Dictionary, 4th
edition, 1995).
The substitution of
one for another as a
creditor so that the
new creditor
succeeds to the
former’s rights
(Webster’s, 1967:
876).
Subrogation arises
when one individual
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Innovation and the Path Not Traveled
William Townsend
The search for metrics to
accurately and compre-
hensively evaluate the value
of innovation has occupied
researchers and managers
since Schumpeter (1934)
identified it as an engine of
organizational growth. The
ability to quantify this value
was limited for decades to
direct monetary values
(profit increases or cost
reductions) and those
related to R&D (R&D
expenditures, R&D assets,
patents, copyrights, etc.).
While the limitations of
these metrics were well
known, the alternatives were
limited. As a greater body of
theoretical and empirical
research developed on the
impacts of innovation on the
firm, a focused search began
for an understanding of the
underlying mechanisms and
way to measure them in the
organization. This explora-
tion led to an understanding
that innovation’s value to an
organization manifested
itself in different ways.
Observational and
theoretical work identified
several classes of innovation
in organization that all
produced value. Empirical
research found that the
value of innovation varied
based upon other contextual
criteria, such as industry
sector, markets, customer
relationship and previous
performance.
As the understanding of
the relationship between
innovation and value evolves
to a more contextually
driven model, so too do the
metrics used to capture it.
The understanding of the
range of value that
innovation provides to the
firm and increasingly
sophisticated ways to
capture it is progressively
greater. The strict reliance
upon cost reduction and
R&D related metrics as the
sole evaluative techniques
has past. Empirical research
confirms this gap between
the aggregate value of
innovation and the value
assessed through traditional
measurement. Monteiro-
Barata (2005) reports an
often-discovered statistic in
the analysis of innovating
firms from two surveys of
Portuguese manufacturing
firms. While both the
INDINOVA and SOTIP
innovation research projects
identified that only a
fraction of the firms
generating product and
process innovation engaged
in R&D. While the
percentage of firms
producing innovations were
fairly consistent between
these studies (36% process
innovation and 27% product
innovation for the
INDINOVA project, and 25.2
percent process innovation
and 20.7% product innova-
tion for the SOTIP project)
the number of companies
engaged in internal R&D
activities is 3.1 percent
according to the SOTIP
survey (p.305).
Models of Innovation
Valuation
Innovation is a localized
phenomenon, defined within
very specific contextual
boundaries in an
organization. Innovation
valuation models do not
necessarily transfer outside
of the context in which they
are found. This makes it
difficult to establish a
generalizable framework
that can be abstracted and
applied to other environ-
ments. An interesting
statistic reported by Hipp
and Grupp (2005) from the
1999 Mannheim Innovation
Panel of German firms,
reflects the localized nature
of much innovation. Of the
1405 firms reporting an
innovation in the past three
years, 34 percent of
manufacturing firms
launched innovations that
were new to the market and
57 percent produced
innovations that were only
new to the firm. This
disparity in the level of
novelty was even more
pronounced in the services
sectors. From the 1080
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satisfies the debt of
another as a result
of a contractual
agreement {whereby}
claims are kept alive
for the benefit of the
party which pays the
debt. Subrogation is
a highly favored
remedy that the
courts are inclined to
extend and apply
liberally. …
Subrogation most
commonly arises in
relation to policies of
insurance; the legal
technique is of more
general application
(Subrogation, 1998). 
The right of subrogation
may be assigned, granting
the right to file a claim or
instigate a lawsuit if the
primary party does not do
so. Legally, subrogation
places another in the place
of the original party with all
the legal rights afforded
thereunder.
Also note that this
substitution does not imply
gain or loss in the above
definitions. Subrogation, as
routinely applied in the
property and casualty
insurance industry, means
the substitution of the
insurer in place of the
insured for the purpose of
claiming indemnification
(recovery) from a negligent
third person for a loss
covered by insurance (Rejda,
2004). Subrogation is often
referred to as the insurer
“stepping into the shoes” of
the insured (Tramountanas,
2002). Property and liability 
insurers have engaged the
principle of indemnity to
recover from negligent
parties amounts paid to
their insureds under their
insurance policies, using
that industry’s standard
that indemnity is a legal
exemption from liability for
damages. The general rule
in the property and liability
industry is that the insurer
is entitled only to the
amount it has paid under
the policy, although the
insurer’s recovery less
expenses incurred during
the pursuit of wrongdoers
escapes taxation. This
insurance-generated
subrogation basis is linked
and becomes relevant only
for contracts of indemnity,
leaving its applicability to
life settlements untested. To
anticipate a challenge
arising out of the require-
ment that a life insurance
contract requires the
insured’s insurable interest
for property and liability
insurance, such a
requirement exists only at
the time the policy is
purchased (Harrington and
Niehaus 2004). Thus
subsequent investors
holding the original
insured’s rights would not
be required to have an
applicable insurable
interest.
Conventional
subrogation originates from
a contract; so does life
settlement. Subrogation,
applied to life settlement
insurance contracts,
nullifies tax application.
Thus, the scope of
subrogation, extended
beyond property and
liability insurance contracts
and into life settlement
insurance contracts, is a
clear and consistent
application. 
A second atypical route
to alternative tax treatment
concerns assignment,
defined as transfer of rights
or property (Black’s Law
Dictionary, 1999). Within
this proposition, a life
settlement has contractual
rights that are considered to
be property and as such can
be transferred to others. In
an assignment, those rights
inure to the investor’s
benefit. "Most contracts
permit an assignment as
long as the other party to
the contract approves the
assignment" (Bennett 2007).
Thus, life settlement
contracts seems to fit with
the interpretation of
assignment that is used in
certain contractual
situations. Some features of
the life settlement market
are set up to insure that the
transfer of rights is
unconditional, subject to
payment of future
premiums. A conditional
transfer of rights would
arise in a contractual
exchange, requiring
consideration that is
vulnerable in case the
assignee breaches the
contract. It would be a
conditional contract since
the original insured
remained responsible for the
performance of the contract
(e.g., payment of continuing
premiums) if future
requirements are involved.
However, a part of life
settlement contracts is the
placement in an escrow
account of the likely future
premiums and the
designation of the investor
as the payee for any
additional premiums. As
with subrogation, there
appears to be no taxable
gain in such a transaction. 
Subrogation or
assignment interpretations
of life settlements are
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apparently untested
applications. Their direct
consequence would be tax-
free treatment of the
proceeds of life insurance
from the insured seller to
life settlement investors
Referring to Figure 3, the
change in tax treatment
would enable the investor to
earn his required after-tax
return with an increased
offer to the insured  policy
seller. Solving for the
investment that would
result in a rate of return of
10.80 percent given tax-free
treatment, the investor
would make an offer of
$598,750, a 19.75 percent
increase over ordinary
income treatment, and an
8.08 percent increase over
capital gains treatment,
freeing additional funding
that previously paid taxes
into direct funding to the
insured, who receives it on a
tax-free basis.10
Conclusion
This article presents
alternative tax treatments
for life settlement
transactions. All tax
treatments presented have
some support in tax
accounting and economic
literature. The current
Internal Revenue Code
embraces a tax treatment
limiting funds to the insured
seller and investors. This
article presents arguments
that such treatment of
proceeds from life
settlement policies to
investors should be taxed as
a capital gain in excess of
basis. Further arguments
are made, consistent with
application of subrogation
and assignment from the
property and liability
industry,  that none of the
proceeds are taxable.
Endnotes
1. The term “viatical
settlement” is used
exclusively for life
insurance sales by the
terminally ill or
chronically ill
policyholder. “Life
settlement” is used for
both life insurance sales
by any senior citizen and
for all life insurance
sales. “Life settlement” is
used in this article even
though it focuses on
settlements for the
terminally- or
chronically-ill, as it is
the more common term
used in practice.
2. While this article
describes the actual
practice of life settlement
companies with respect
to closing costs, who
pays the closing costs is
a matter of convenience
in the transaction rather
than a factor that
actually affects the
funding to the insured.
If the closing costs were
paid by the investor,
then the investor would
be willing to pay less for
the investment,
mitigating any additional
proceeds to the insured
from this arrangement. 
3. The heirs have been
characterized as “losers”
in life settlement
transactions. However,
since they, presumably,
did not originally pay the
premiums and could
alternately fund the
insured/policyholder to
preserve their right to
the death benefit, a life
settlement transaction
becomes an alternative
when the liquidity
benefits predominate. 
4. There are also estate tax
consequences to life
insurance, but these
depend on many factors
and are outside of the
scope of this article. 
5. The IRS in IRC section
101 (g) defines
"terminally ill" as one
who is medically
certified to have an
expected life of
twenty-four months or
less. However, the tax
benefit is also extended
to the "chronically ill" if
there is an annual
certification that the
person is unable to
perform two activities of
daily living or requires
supervision due to
cognitive impairment
and the proceeds are
used to pay for qualified
long-term care. Partial
exclusion is available
when proceeds are
received periodically. 
6. The tax treatment for
senior citizens who do
not qualify as terminally
ill or chronically ill is
described in Goldstein,
Harter, and Holaday
(2006) and Magner and
Leimberg (2007). 
7. While the theoretical
discussion assumes the
survival matches the
maximum life
expectancy of five years,
other survival terms
affect the basis of the life
settlement investment
due to the impact of
premiums. If the
survival is less than five
years, then unused
premiums are paid to
the investor and the
basis is decreased. If the
survival is more than
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five years, then
premiums are paid as
due by the investor and
the basis is increased.
Calculations in Figure 3
include premium effects. 
8. This example assumes
there would be no
material changes in
closing costs to the
broker/life settlement
company. 
9. A tertiary market is not
well-established at this
time. Life settlement
investors are advised
that life settlements are
illiquid investments to
be held until their
maturity at the death of
the insured. However,
transactions between
institutional investors
and life settlement
companies have
included securitized
portfolios of life
settlements which
facilitate a tertiary
market (Legacy Benefits
2007). 
10. This example assumes
there would be no
material changes in
closing costs to the
broker/life settlement
company. 
References
Bennett, S. (2007).
Assigning a contract.
lawyers.com. New
Providence, NJ:
Martindale-Hubbell.
Retrieved from
<http://contracts.lawyer
s.com/Assigning-A-
Contract.html on
8/6/2007>.
Black’s Law Dictionary, 7th
edition. 1999. West
Group.
Encarta. (2007).
Subrogation. Redmond,
WA: Microsoft Corpora-
tion. Retrieved from
<http://encarta.msn.co
m/dictionary_18617165
41/subrogation.html on
8/6/2007>.
Estate of Rath v. U.S. (1979).
608 F. 2d. 254, 6th
Circuit.
Gallun v. Commissioner.
(1964). 327 F. 2d. 809,
7th Circuit.
Goldstein, A., Harter, L., &
Holaday, D. (2006). Sell
your policy? Trusts &
Estates. 145
(September): 24-29.
Harrington, S. E. &
Niehaus, G. R. (2004).
Risk management and
insurance, 2nd edition.
New York: McGraw-
Hill/Irwin. 
Jensen, M., Kaplan, S. &
Stiglin, L. (1989). Effects
of LBOs on tax revenues
of the U.S. treasury. Tax
Analysts/Tax Notes.
339-345.
Legacy benefits concludes
$148,000,000 life
settlement portfolio sale
to institutional investor.
(2007). Business Wire
(July 17) retrieved from
ABI/ProQuest on
7/20/2007 
Life Settlement Association.
(2007). Member
companies. Orlando,
Florida: Life Settlement
Association. Retrieved
from://www
.lisassociation.org/public
/member_companies/
index.html on
12/27/2007.
Life Settlement Brokers.
(2007). National
Underwriter. Life &
Health. 111 (17): S22.
Magner, J. C. & Leimberg,
S. R. (2007). Life
settlement transactions:
Important tax and legal
issues to consider.
Estate Planning. 34
(April): 3-12.
Magner, J. & Leimberg, S.
R. (2006). Life settlement
transaction: Important
tax and legal issues
advisers and fiduciaries
must consider. The
Insurance Tax Review
Magazine. (December):
807-816. retrieved from
LexisNexis Academic
8/6/2007. 
Pacific Coast Gas
Association. (1990).
Transportation
transaction guidelines
glossary of terms.
retrieved from Paiute
Pipeline Company at
http://www.paiutepipeli
ne.com/ on 8/1/2007.
Raby, B. & Raby, W. (2000).
The tax treatment of life
insurance settlements.
The Insurance Tax
Review (September)
retrieved from
LexisNexis Academic on
8/6/2007.
20 Summer 2009 Southern Business Review
apparently untested
applications. Their direct
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free treatment of the
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Referring to Figure 3, the
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offer to the insured  policy
seller. Solving for the
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treatment, the investor
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increase over ordinary
income treatment, and an
8.08 percent increase over
capital gains treatment,
freeing additional funding
that previously paid taxes
into direct funding to the
insured, who receives it on a
tax-free basis.10
Conclusion
This article presents
alternative tax treatments
for life settlement
transactions. All tax
treatments presented have
some support in tax
accounting and economic
literature. The current
Internal Revenue Code
embraces a tax treatment
limiting funds to the insured
seller and investors. This
article presents arguments
that such treatment of
proceeds from life
settlement policies to
investors should be taxed as
a capital gain in excess of
basis. Further arguments
are made, consistent with
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and assignment from the
property and liability
industry,  that none of the
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describes the actual
practice of life settlement
companies with respect
to closing costs, who
pays the closing costs is
a matter of convenience
in the transaction rather
than a factor that
actually affects the
funding to the insured.
If the closing costs were
paid by the investor,
then the investor would
be willing to pay less for
the investment,
mitigating any additional
proceeds to the insured
from this arrangement. 
3. The heirs have been
characterized as “losers”
in life settlement
transactions. However,
since they, presumably,
did not originally pay the
premiums and could
alternately fund the
insured/policyholder to
preserve their right to
the death benefit, a life
settlement transaction
becomes an alternative
when the liquidity
benefits predominate. 
4. There are also estate tax
consequences to life
insurance, but these
depend on many factors
and are outside of the
scope of this article. 
5. The IRS in IRC section
101 (g) defines
"terminally ill" as one
who is medically
certified to have an
expected life of
twenty-four months or
less. However, the tax
benefit is also extended
to the "chronically ill" if
there is an annual
certification that the
person is unable to
perform two activities of
daily living or requires
supervision due to
cognitive impairment
and the proceeds are
used to pay for qualified
long-term care. Partial
exclusion is available
when proceeds are
received periodically. 
6. The tax treatment for
senior citizens who do
not qualify as terminally
ill or chronically ill is
described in Goldstein,
Harter, and Holaday
(2006) and Magner and
Leimberg (2007). 
7. While the theoretical
discussion assumes the
survival matches the
maximum life
expectancy of five years,
other survival terms
affect the basis of the life
settlement investment
due to the impact of
premiums. If the
survival is less than five
years, then unused
premiums are paid to
the investor and the
basis is decreased. If the
survival is more than
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five years, then
premiums are paid as
due by the investor and
the basis is increased.
Calculations in Figure 3
include premium effects. 
8. This example assumes
there would be no
material changes in
closing costs to the
broker/life settlement
company. 
9. A tertiary market is not
well-established at this
time. Life settlement
investors are advised
that life settlements are
illiquid investments to
be held until their
maturity at the death of
the insured. However,
transactions between
institutional investors
and life settlement
companies have
included securitized
portfolios of life
settlements which
facilitate a tertiary
market (Legacy Benefits
2007). 
10. This example assumes
there would be no
material changes in
closing costs to the
broker/life settlement
company. 
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satisfies the debt of
another as a result
of a contractual
agreement {whereby}
claims are kept alive
for the benefit of the
party which pays the
debt. Subrogation is
a highly favored
remedy that the
courts are inclined to
extend and apply
liberally. …
Subrogation most
commonly arises in
relation to policies of
insurance; the legal
technique is of more
general application
(Subrogation, 1998). 
The right of subrogation
may be assigned, granting
the right to file a claim or
instigate a lawsuit if the
primary party does not do
so. Legally, subrogation
places another in the place
of the original party with all
the legal rights afforded
thereunder.
Also note that this
substitution does not imply
gain or loss in the above
definitions. Subrogation, as
routinely applied in the
property and casualty
insurance industry, means
the substitution of the
insurer in place of the
insured for the purpose of
claiming indemnification
(recovery) from a negligent
third person for a loss
covered by insurance (Rejda,
2004). Subrogation is often
referred to as the insurer
“stepping into the shoes” of
the insured (Tramountanas,
2002). Property and liability 
insurers have engaged the
principle of indemnity to
recover from negligent
parties amounts paid to
their insureds under their
insurance policies, using
that industry’s standard
that indemnity is a legal
exemption from liability for
damages. The general rule
in the property and liability
industry is that the insurer
is entitled only to the
amount it has paid under
the policy, although the
insurer’s recovery less
expenses incurred during
the pursuit of wrongdoers
escapes taxation. This
insurance-generated
subrogation basis is linked
and becomes relevant only
for contracts of indemnity,
leaving its applicability to
life settlements untested. To
anticipate a challenge
arising out of the require-
ment that a life insurance
contract requires the
insured’s insurable interest
for property and liability
insurance, such a
requirement exists only at
the time the policy is
purchased (Harrington and
Niehaus 2004). Thus
subsequent investors
holding the original
insured’s rights would not
be required to have an
applicable insurable
interest.
Conventional
subrogation originates from
a contract; so does life
settlement. Subrogation,
applied to life settlement
insurance contracts,
nullifies tax application.
Thus, the scope of
subrogation, extended
beyond property and
liability insurance contracts
and into life settlement
insurance contracts, is a
clear and consistent
application. 
A second atypical route
to alternative tax treatment
concerns assignment,
defined as transfer of rights
or property (Black’s Law
Dictionary, 1999). Within
this proposition, a life
settlement has contractual
rights that are considered to
be property and as such can
be transferred to others. In
an assignment, those rights
inure to the investor’s
benefit. "Most contracts
permit an assignment as
long as the other party to
the contract approves the
assignment" (Bennett 2007).
Thus, life settlement
contracts seems to fit with
the interpretation of
assignment that is used in
certain contractual
situations. Some features of
the life settlement market
are set up to insure that the
transfer of rights is
unconditional, subject to
payment of future
premiums. A conditional
transfer of rights would
arise in a contractual
exchange, requiring
consideration that is
vulnerable in case the
assignee breaches the
contract. It would be a
conditional contract since
the original insured
remained responsible for the
performance of the contract
(e.g., payment of continuing
premiums) if future
requirements are involved.
However, a part of life
settlement contracts is the
placement in an escrow
account of the likely future
premiums and the
designation of the investor
as the payee for any
additional premiums. As
with subrogation, there
appears to be no taxable
gain in such a transaction. 
Subrogation or
assignment interpretations
of life settlements are
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